{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T17:11:49Z","timestamp":1786554709847,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T00:00:00Z","timestamp":1685750400000},"content-version":"am","delay-in-days":306,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jiac.2022.05.008","type":"journal-article","created":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T16:07:44Z","timestamp":1653235664000},"page":"1092-1097","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["AAUS guideline for acute uncomplicated pyelonephritis"],"prefix":"10.1016","volume":"28","author":[{"given":"Katsumi","family":"Shigemura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyohito","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2022.05.008_bib1","series-title":"Guidelines on urological infections","first-page":"8","author":"Grabe","year":"2014"},{"key":"10.1016\/j.jiac.2022.05.008_bib2","series-title":"Antibiotic treatment of uncomplicated urinary tract infection in premenopausal women","first-page":"171","author":"Naber","year":"2009"},{"key":"10.1016\/j.jiac.2022.05.008_bib3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the infectious disease society of America and the European society for microbiology and infectious diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2022.05.008_bib4","series-title":"Kidney bladder and prostate","first-page":"p34","author":"Gilbert","year":"2014"},{"key":"10.1016\/j.jiac.2022.05.008_bib5","series-title":"The JAID\/JSC guide to clinical management of infectious disease 2011","author":"Aoki","year":"2012"},{"issue":"9788","key":"10.1016\/j.jiac.2022.05.008_bib6","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(11)60401-7","article-title":"Society's failure to protect a precious resource: antibiotics","volume":"378","author":"Carlet","year":"2011","journal-title":"Lancet"},{"issue":"Suppl","key":"10.1016\/j.jiac.2022.05.008_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijantimicag.2011.09.002","article-title":"Antibiotic policy","volume":"38","author":"Gyssens","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2022.05.008_bib8","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1089\/mdr.2011.0139","article-title":"Fluoroquinolone resistance in uncomplicated acute pyelonephritis:epidemiology and clinical impact","volume":"18","author":"Shin","year":"2012","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.jiac.2022.05.008_bib9","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/QCO.0b013e3283398dc1","article-title":"Extended-spectrum [beta]-lactamas producing Escherichia coli: changing epidemiology and clinical impact","volume":"23","author":"Oteo","year":"2010","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.jiac.2022.05.008_bib10","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"What is \"quality of evidence\" and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jiac.2022.05.008_bib11","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jiac.2022.05.008_bib12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ijantimicag.2009.04.012","article-title":"An international survey on the antimicrobial resistance of pathogen involved in uncomplicated urinary tract infection","volume":"34","author":"Schit","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2022.05.008_bib13","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.eururo.2008.05.010","article-title":"Surveillance study in europe and Brazil on clinical aspects and antimicrobial resistance epidemiology in females with cystitis (ARESC): implications for empiric therapy","volume":"54","author":"Naber","year":"2008","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.jiac.2022.05.008_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0177266","article-title":"Antibiotic resistance rates and physician antibiotic prescription patterns of uncomplicated urinary tract infections in southern Chinese primary care","volume":"12","author":"Wong","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jiac.2022.05.008_bib15","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jiac.2017.11.013","article-title":"GPIU Asian Investigators. Aspects of urinary tract infections and antimicrobial resistance in hospitalized urology patients in Asia: 10-Year results of the Global Prevalence Study of Infections in Urology (GPIU)","volume":"24","author":"Choe","year":"2018","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2022.05.008_bib16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s41182-020-00251-6","article-title":"Multidrug-resistant and extended-spectrum beta-lactamase-producing uropathogens in children in Bhaktapur, Nepal","volume":"48","author":"Raya","year":"2020","journal-title":"Trop Med Health"},{"issue":"8","key":"10.1016\/j.jiac.2022.05.008_bib17","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3390\/antibiotics9080438","article-title":"Gram-negative organisms from patients with community-acquired urinary tract infections and associated risk factors for antimicrobial resistance: a single-center retrospective observational study in Japan","volume":"9","author":"Kanda","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jiac.2022.05.008_bib18","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2147\/IDR.S203572","article-title":"Susceptibilities of Gram-negative bacilli from hospital- and community-acquired intra-abdominal and urinary tract infections: a 2016\u20132017 update of the Chinese SMART study","volume":"12","author":"Zhang","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jiac.2022.05.008_bib19","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jinf.2011.06.007","article-title":"A simple model to predict bacteremia in women with acute pyelonephritis","volume":"63","author":"Kim","year":"2011","journal-title":"J Infect"},{"key":"10.1016\/j.jiac.2022.05.008_bib20","author":"Fulop"},{"key":"10.1016\/j.jiac.2022.05.008_bib21","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/clind\/15.Supplement_1.S216","article-title":"Evaluation of new anti-infective drugs for the treatment of UTI","volume":"15","author":"Rubin","year":"1992","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2022.05.008_bib22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.urology.2008.07.061","article-title":"Clinical implication of serum C-reactive protein in patients with uncomplicated acute pyelonephritis as marker of prolonged hospitalization and recurrence","volume":"73","author":"Yang","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.jiac.2022.05.008_bib23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10156-010-0116-y","article-title":"Selection of first-line i.v.antibiotics for acute pyelonephritis in patient required emergency hospital admission","volume":"14","author":"Yasufuku","year":"2011","journal-title":"J Infect Chemother"},{"issue":"6","key":"10.1016\/j.jiac.2022.05.008_bib24","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1469-0691.2009.02955.x","article-title":"Can C-reactive protein, procalcitonin and mid-regional pro-atrial natriuretic peptide measurements guide choice of in-patients or out-patients care in acute pyelonephritis? Biomarkers In Sepsis (BIS) multicentrestudy","volume":"16","author":"Claessens","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiac.2022.05.008_bib25","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.medmal.2014.03.003","article-title":"Antibiotic resistance in adult female patients hospitalized for acute pyelonephritis: rates and predicting factors","volume":"44","author":"Etienne","year":"2014","journal-title":"Med Maladies Infect"},{"key":"10.1016\/j.jiac.2022.05.008_bib26","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jiac.2022.05.008_bib27","doi-asserted-by":"crossref","first-page":"20","DOI":"10.7326\/0003-4819-142-1-200501040-00008","article-title":"Risk factors associated with acute pyelonephritis in healthy women","volume":"142","author":"Scholes","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jiac.2022.05.008_bib28","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s10156-009-0721-9","article-title":"Efficacy of treatment with carbapenemes and third-generation cephalosporins for patients with febrile complicated pyelonephritis","volume":"15","author":"Takahashi","year":"2009","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2022.05.008_bib29","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1128\/AAC.06212-11","article-title":"Empirical use of ciprofloxacin for acute uncomplicated pyelonephritis caused by Escherichia coli in communities where the prevalence of fluoroquinolone resistance is high","volume":"56","author":"Jeon","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"9840","key":"10.1016\/j.jiac.2022.05.008_bib30","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0140-6736(12)60608-4","article-title":"Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomized, open label and double-blind, placebo-controlled, non-inferiority trial","volume":"380","author":"Sandberg","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jiac.2022.05.008_bib31","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1001\/jama.283.12.1583","article-title":"Comparison of ciprofloxacin (7 days) and trimethoprimsulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial","volume":"283","author":"Talan","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jiac.2022.05.008_bib32","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1185\/030079907X233340","article-title":"A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and\/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis","volume":"23","author":"Klausner","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jiac.2022.05.008_bib33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.urology.2007.09.002","article-title":"A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400\/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis","volume":"71","author":"Peterson","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.jiac.2022.05.008_bib34","first-page":"365","article-title":"Efficacy and safety of sitafloxacin in patients with urinary tract infections","volume":"65","author":"Matsumoto","year":"2012","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.jiac.2022.05.008_bib35","series-title":"JAID\/JSC guide for infectious diseases","year":"2019"},{"key":"10.1016\/j.jiac.2022.05.008_bib36","first-page":"29","article-title":"Cefpodoximeproxetil in patients with acute uncomplicatedpyelonephritis. International, prospective, randomized comparative study versus ciprofloxacin ingeneral practice","volume":"10","author":"Naber","year":"2001","journal-title":"Chemother J"},{"key":"10.1016\/j.jiac.2022.05.008_bib37","first-page":"1","article-title":"Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents","author":"Bader","year":"2019","journal-title":"Postgrad Med"},{"key":"10.1016\/j.jiac.2022.05.008_bib38","series-title":"EAU guidelines on urological infections","author":"Bonkat","year":"2017"},{"key":"10.1016\/j.jiac.2022.05.008_bib39","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jiac.2018.10.009","article-title":"The efficacy and safety of tazobactam\/ceftolozane in Japanese patients with uncomplicated pyelonephritis and complicated urinary tract infection","volume":"25","author":"Arakawa","year":"2019","journal-title":"J Infect Chemother"},{"issue":"3","key":"10.1016\/j.jiac.2022.05.008_bib40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000487645","article-title":"The 2017 update of the German clinical guideline on epidemiology, diagnostics, therapy, prevention, and management of uncomplicated urinary tract infections in adult patients Part II: therapy and prevention","volume":"100","author":"Kranz","year":"2018","journal-title":"Urol Int"},{"key":"10.1016\/j.jiac.2022.05.008_bib41","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jinf.2010.10.009","article-title":"Impact of discordant empirical therapy on outcome of community-acquired bacteremic acute pyelonephritis","volume":"62","author":"Lee","year":"2011","journal-title":"J Infect"},{"issue":"Suppl 2","key":"10.1016\/j.jiac.2022.05.008_bib42","first-page":"ii67","article-title":"Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by an appropriate oral therapy","volume":"53","author":"Wells","year":"2004","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl A","key":"10.1016\/j.jiac.2022.05.008_bib43","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jac\/36.suppl_A.145","article-title":"Empirical monotherapy with meropenem in serious bacterial infections. Meropenem Study Group","volume":"36","author":"Mouton","year":"1995","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl B","key":"10.1016\/j.jiac.2022.05.008_bib44","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/jac\/32.suppl_B.123","article-title":"Low-dosage cefepime as treatment for serious bacterial infections","volume":"32","author":"Giamarellou","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2022.05.008_bib45","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0924-8579(01)00481-2","article-title":"Piperacillin 2 g\/tazobactam 0.5 g is as effective as imipenem 0.5 g\/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections","volume":"19","author":"Naber","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2022.05.008_bib46","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1128\/AAC.00837-08","article-title":"Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for the treatment of complicated lower urinary tract infection and pyelonephritis","volume":"53","author":"Naber","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2022.05.008_bib47","first-page":"37434","article-title":"Labeling and prescription drug advertising: content and format for labeling for human prescription drugs","volume":"44","year":"1979","journal-title":"Fed Regist"},{"key":"10.1016\/j.jiac.2022.05.008_bib48","series-title":"Drugs in pregnancy and lactation","author":"Briggs","year":"2014"},{"key":"10.1016\/j.jiac.2022.05.008_bib49","author":"United States National Library of Medicine"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X2200157X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X2200157X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:05:22Z","timestamp":1761159922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X2200157X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1341321X2200157X"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2022.05.008","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AAUS guideline for acute uncomplicated pyelonephritis","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2022.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}